199 related articles for article (PubMed ID: 32279192)
1. Nintedanib-induced glomerular microangiopathy: a case report.
Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
[TBL] [Abstract][Full Text] [Related]
2. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
[TBL] [Abstract][Full Text] [Related]
3. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib in idiopathic pulmonary fibrosis.
Woodcock HV; Maher TM
Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
[TBL] [Abstract][Full Text] [Related]
5. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
7. Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report.
Ismail I; Nigam S; Parnham A; Srinivasa V
J Med Case Rep; 2017 Aug; 11(1):214. PubMed ID: 28779751
[TBL] [Abstract][Full Text] [Related]
8. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Wind S; Schmid U; Freiwald M; Marzin K; Lotz R; Ebner T; Stopfer P; Dallinger C
Clin Pharmacokinet; 2019 Sep; 58(9):1131-1147. PubMed ID: 31016670
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib-Induced Renal Thrombotic Microangiopathy.
Fujita T; Nakagawa H; Yokota T; Umetani J; Nagawa D; Nakata M; Narita-Kinjo I; Murakami R; Shimada M; Nakamura N; Tomita H
Case Rep Nephrol Dial; 2021; 11(2):227-232. PubMed ID: 34414215
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.
Ameri P; Tini G; Spallarossa P; Mercurio V; Tocchetti CG; Porto I
Br J Clin Pharmacol; 2021 Oct; 87(10):3690-3698. PubMed ID: 33620103
[TBL] [Abstract][Full Text] [Related]
15. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib: first global approval.
McCormack PL
Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Schmid U; Doege C; Dallinger C; Freiwald M
Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
